What were the results of the LIBRETTO-432 trial?

The trial showed Retevmo reduced the risk of recurrence or death in early-stage RET fusion-positive NSCLC patients.

Is Retevmo currently approved?

Yes, for advanced lung cancer; new data supports early-stage use.

VERVE-102 is an experimental gene therapy from Eli Lilly targeting cardiovascular disease.

Eli Lilly's Retevmo Cuts Lung Cancer Recurrence Risk in Phase 3

Eli Lilly announced positive Phase 3 results for Retevmo in early-stage lung cancer and early data for gene therapy VERVE-102 targeting cardiovascular disease.

June 3, 2026

2 min read

Source: Simply Wall St.

Key Numbers

risk reduction

not disclosed

patient population

RET fusion-positive NSCLC

Eli Lilly (NYSE:LLY) reported Phase 3 data from the LIBRETTO-432 trial showing that Retevmo (selpercatinib) significantly reduced the risk of recurrence or death in patients with early-stage RET fusion-positive non-small cell lung cancer (NSCLC). The results position Retevmo as a potential new adjuvant standard of care for this genetically defined patient population.

The Product

Retevmo is an oral selective RET inhibitor. The trial demonstrated efficacy in reducing recurrence or death compared to placebo, making it a candidate for the new standard of care in adjuvant treatment.

Pricing and Availability

Lilly has not yet disclosed pricing or regulatory timelines. The company is expected to file for FDA approval in the coming months.

Competition

Retevmo competes with Roche's Gavreto (pralsetinib), but Retevmo is the first to show benefit in early-stage lung cancer.

Potential Impact on Lilly

This breakthrough expands Retevmo's potential beyond advanced settings, diversifying Lilly's revenue stream and reducing reliance on obesity drugs like Mounjaro and Zepbound.

Frequently Asked Questions

Retevmo (selpercatinib) is an oral drug targeting RET gene mutations, used for non-small cell lung cancer.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.